A Comparison of the Ocular Hypotensive Efficacy of Twice-Daily 0.25% Levobunolol to 0.5% Timolol in Patients Previously Treated with 0.5% Timolol

Cc, Beehler; Wc, Stewart; Dk, Macdonald; Ta, Croyle; Cs, Ostrov; Eg, Rosanelli; As, Crandall; Tl, Iacono; Lue, John C.; Ep, Kelley

doi:10.1097/00061198-199201040-00005

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the incidence of uveitis over ten months in our population was still greater than most previous b-blocker trials (Dubiner et al 1996;Stewart et al 1996;1997;Beehler et al 1992;Melles & Wong 1994). Consequently, an association of latanoprost to the uveitis in our patients cannot be ruled out.…”

Section: Discussioncontrasting

confidence: 53%

“…The incidence in our study also is higher than the 0% incidence in several previous prospective multicenter glaucoma trials studying other classes of medicines, including ß-blockers and a 2 -agonists (Dubiner et al 1996;Stewart et al 1996;1997;Beehler et al 1992). In addition, Beck and associates in the United States noted in a population of 5831 patients on ß-blocker therapy that none had uveitis (Beck 1996).…”

Section: Discussioncontrasting

confidence: 43%

See 1 more Smart Citation

Latanoprost 0.005% and anterior segment uveitis

Smith¹,

Pruitt²,

Sine³

et al. 1999

Acta Ophthalmologica Scandinavica

Self Cite

View full text Add to dashboard Cite

ABSTRACT.Purpose: To evaluate the association of latanoprost with anterior chamber uveitis in glaucoma patients. Methods: We retrospectively reviewed 527 charts in latanoprost treated patients with: no prior uveitis (Group 1); prior uveitis but were inactive at the time of the study (Group 2); and active uveitis (Group 3). Results: In Group 1 five (1.0%) of 505 patients developed uveitis after beginning latanoprost. The uveitis was trace to 1π cell in severity and delayed in onset 99.8∫73.9 days. In Group 2 three of 13 (23.1%) patients developed delayed uveitis (trace to 1π cell). In Group 3 zero of nine (0%) patients had worsened inflammation and the intraocular pressure remained unchanged (22.8∫7.8 mmHg to 22.0∫7.3 mmHg) after beginning latanoprost (pΩ0.38). Conclusion: In patients without a prior history a mild delayed uveitis with latanoprost treatment may develop rarely. In patients with a uveitis history, a mild delayed exacerbation potentially may occur and the intraocular pressure may not be decreased in active uveitis.Key words: anterior segment uveitis -Latanoprost 0.005% -adverse events -intraocular inflammation -intraocular pressure.

show abstract

Section: Discussioncontrasting

confidence: 53%

Section: Discussioncontrasting

confidence: 43%

Latanoprost 0.005% and anterior segment uveitis

Smith¹,

Pruitt²,

Sine³

et al. 1999

Acta Ophthalmologica Scandinavica

Self Cite

View full text Add to dashboard Cite

show abstract

“…Clinical studies have shown that equal concentrations of levobunolol BID and timolol solution BID produce comparable IOP-lowering effects (6).…”

Section: Introductionmentioning

confidence: 99%

A Comparison of the Efficacy and Tolerability of 0.5% Timolol Maleate Ophthalmic Gel-Forming Solution QD and 0.5% Levobunolol Hydrochloride BID in Patients with Ocular Hypertension or Open-Angle Glaucoma

Halper

Johnson-Pratt

Dobbins

et al. 2002

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

The purpose of this study was to compare the ocular hypotensive efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution (timolol gel) and 0.5% levobunolol hydrochloride (levobunolol). This was a randomized, double-masked, multi-center, active-controlled, 2-period, crossover study. After a 3-week, single-masked placebo run-in phase, patients with ocular hypertension or open-angle glaucoma and an intraocular pressure (IOP) > or = 22 mmHg were randomized to receive timolol gel QD or levobunolol BID for 6 weeks followed by a 3-week, placebo washout period. Patients were then crossed over to the alternate treatment for 6 weeks. IOP and heart rate (HR) were measured at 3 and 6 weeks after the start of therapy with either timolol gel or levobunolol. Of 133 patients randomized, 116 received both treatments. Timolol gel QD was comparable to levobunolol BID in reducing trough and peak IOP. At trough, HR was marginally increased with timolol gel and was decreased with levobunolol (p = < 0.001). At peak, HR was decreased with both treatments, but the decrease was significantly less with timolol gel than with levobunolol (p = 0.049). Significantly more patients experienced at least one adverse event (p = 0.024), adverse events related to special senses (p = 0.002), and burning and stinging (p < 0.001) with levobunolol compared to timolol gel. The study demonstrates that timolol gel QD has IOP-lowering effects comparable to those of levobunolol BID with fewer adverse experiences and less effect on HR.

show abstract

Daily Cost of β-Adrenergic Blocker Therapy

Stewart¹

1997

Arch Ophthalmol

View full text Add to dashboard Cite

A Comparison of the Ocular Hypotensive Efficacy of Twice-Daily 0.25% Levobunolol to 0.5% Timolol in Patients Previously Treated with 0.5% Timolol

Cited by 3 publications

References 0 publications

Latanoprost 0.005% and anterior segment uveitis

Latanoprost 0.005% and anterior segment uveitis

A Comparison of the Efficacy and Tolerability of 0.5% Timolol Maleate Ophthalmic Gel-Forming Solution QD and 0.5% Levobunolol Hydrochloride BID in Patients with Ocular Hypertension or Open-Angle Glaucoma

Daily Cost of β-Adrenergic Blocker Therapy

Contact Info

Product

Resources

About